1. Upregulation of ACE2-ANG-(1-7)-Mas axis in jejunal enterocytes of type 1 diabetic rats: implications for glucose transport.
- Author
-
Wong TP, Ho KY, Ng EK, Debnam ES, and Leung PS
- Subjects
- Angiotensin I administration & dosage, Angiotensin I genetics, Angiotensin I therapeutic use, Angiotensin-Converting Enzyme 2, Animals, Biological Transport drug effects, Caco-2 Cells, Cells, Cultured, Diabetes Mellitus, Type 1 metabolism, Enterocytes drug effects, Enterocytes pathology, Glucose metabolism, Humans, Hyperglycemia prevention & control, Hypoglycemic Agents administration & dosage, Hypoglycemic Agents metabolism, Hypoglycemic Agents therapeutic use, In Vitro Techniques, Injections, Intravenous, Jejunum drug effects, Jejunum pathology, Male, Peptide Fragments administration & dosage, Peptide Fragments genetics, Peptide Fragments therapeutic use, Peptidyl-Dipeptidase A genetics, Protein Kinase C antagonists & inhibitors, Protein Kinase Inhibitors pharmacology, Proto-Oncogene Mas, Proto-Oncogene Proteins antagonists & inhibitors, Proto-Oncogene Proteins genetics, RNA, Messenger metabolism, Rats, Rats, Wistar, Receptors, G-Protein-Coupled antagonists & inhibitors, Receptors, G-Protein-Coupled genetics, Angiotensin I metabolism, Diabetes Mellitus, Type 1 drug therapy, Enterocytes metabolism, Jejunum metabolism, Peptide Fragments metabolism, Peptidyl-Dipeptidase A metabolism, Proto-Oncogene Proteins metabolism, Receptors, G-Protein-Coupled metabolism, Up-Regulation
- Abstract
The inhibitory effects of the angiotensin-converting enzyme (ACE)-ANG II-angiotensin type 1 (AT₁) receptor axis on jejunal glucose uptake and the reduced expression of this system in type 1 diabetes mellitus (T1DM) have been documented previously. The ACE2-ANG-(1-7)-Mas receptor axis is thought to oppose the actions of the ACE-ANG II-AT₁ receptor axis in heart, liver, and kidney. However, the possible involvement of the ACE2-ANG-(1-7)-Mas receptor system on enhanced jejunal glucose transport in T1DM has yet to be determined. Rat everted jejunum and Caco-2 cells were used to determine the effects of ANG-(1-7) on glucose uptake and to study the ACE2-ANG-(1-7)-Mas receptor signaling pathway. Expression of target gene and protein in jejunal enterocytes and human Caco-2 cells were quantified using real-time PCR and Western blotting. T1DM increased jejunal protein and mRNA expression of ACE2 (by 59 and 173%, respectively) and Mas receptor (by 55 and 100%, respectively) in jejunum. One millimolar ANG-(1-7) reduced glucose uptake in jejunum and Caco-2 cells by 30.6 and 30.3%, respectively, effects that were abolished following addition of 1 μM A-779 (a Mas receptor blocker) or 1 μM GF-109203X (protein kinase C inhibitor) to incubation buffer for jejunum or Caco-2 cells, respectively. Finally, intravenous treatment of animals with ANG-(1-7) significantly improved oral glucose tolerance in T1DM but not control animals. In conclusion, enhanced activity of the ACE2-ANG-(1-7)-Mas receptor axis in jejunal enterocytes is likely to moderate the T1DM-induced increase in jejunal glucose uptake resulting from downregulation of the ACE-ANG II-AT₁ receptor axis. Therefore, altered activity of both ACE and ACE2 systems during diabetes will determine the overall rate of glucose transport across the jejunal epithelium.
- Published
- 2012
- Full Text
- View/download PDF